Select Page

Lung Cancer Awareness Month: Progress in early screening and diagnostics, plus smoking cessation programs to help reduce health disparities
“SEATTLE — October 24, 2023 — As Lung Cancer Awareness Month begins in November, experts at Fred Hutchinson Cancer Center remain committed to advancing early screening, helping people quit smoking and developing new ways to detect and treat lung cancer.”

VA encouraging veterans to get lung cancer screenings
“November is Lung Cancer Awareness Month, and included in that is National Lung Cancer Screening Day on Nov. 11. Ahead of that, the U.S. Department of Veterans Affairs is urging veterans to get screened for what is the No. 1 cancer killer among veterans – and veterans are at twice the risk as non-veterans of developing lung cancer.”

Trends in Lung Cancer Incidence Among Women and Men in the United States
“In a study reported in a research letter in JAMA Oncology, Jemal et al found that rates of lung cancer declined more in men vs women in the United States in recent years, such that incidence is now higher in women vs men aged ≤ 55 years.”

CHI St. Vincent offers lung cancer screens on Nov. 11
CHI St. Vincent Hot Springs will join hospitals and clinics across the country on National Lung Cancer Screening Day with a health fair and screenings from 9 a.m. to noon on Nov. 11.

Under Armpit Bump Signals Lung Cancer for NJ Woman
“Debbie Cihoski was enjoying the warm summer weather and wearing sleeveless dresses to work, when she realized a persistent itchy bump under her left armpit wouldn’t let up.”

New Study Shows Adults Treated for Non-Small Cell Lung Cancer Vulnerable to Hazards of Wildfires
“Newswise — ATLANTA, October 27, 2023 — New research by scientists at the American Cancer Society (ACS) and the University of California, San Francisco, shows individuals in the United States undergoing radiotherapy for non-small cell lung cancer (NSCLC) who are exposed to wildfires near the treating facility have worse overall survival than unexposed individuals.”

Is it cancer or not? Clinic in Peoria provides quick results and supportive treatment
“A leader in cancer care for central Illinois, James B. Gerstner, MD, found himself on the patient side of cancer care about three months ago at the Suspicion of Cancer Clinic located at Carle Health Methodist Hospital in Peoria.”

How Dangerous Is It for Lung Cancer Patients to Skip Radiation Treatments?
“TUESDAY, Oct. 25, 2022 (HealthDay News) — As doctors work toward developing more personalized cancer care, a new study looks at whether lung cancer patients can miss a few days of radiation treatment and make them up with a higher dose.”

Personalized lung cancer radiotherapy proves safer, more effective
“Stereotactic ablative radiotherapy (SABR) is a precision cancer treatment that delivers highly focused, intense radiation doses over just a few treatment sessions. Also known as stereotactic body radiation therapy, SABR is the standard-of-care for inoperable early-stage non-small cell lung cancer (NSCLC). However, it can confer a higher risk of severe-to-potentially fatal toxicities than more conventionally delivered radiotherapy.”

First Immunotherapy Success in TKI-Resistant Lung Cancer Setting Demonstrates Power of AI-driven Immune Phenotyping by Lunit SCOPE IO – newly published in JCO
“SEOUL, Korea South — Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a significant breakthrough in the treatment of non-small cell lung cancer (NSCLC) with resistance to certain targeted therapies.”

Free lung cancer screening to be held at Ascension Genesys Hospital
“GRAND BLANC TWP, MI – November is Lung Cancer Awareness month and Ascension Genesys Hospital is offering no-cost, low dose CT screenings of the lungs.”

Perioperative Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable Non–Small Cell Lung Cancer
“A perioperative regimen of neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab achieved a statistically significant and clinically meaningful improvement in event-free survival compared with neoadjuvant chemotherapy plus placebo followed by surgery and adjuvant placebo in patients with resectable stage IIA to IIIB non–small cell lung cancer (NSCLC).”